APAC NSCLC and Epilepsy Therapeutics Market 2019 Forecasts

DALLAS, March 15, 2014 /PRNewswire/ --

ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research reports in its store.

According to Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability research report available at http://www.reportsnreports.com/reports/276612-epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability.html, the value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

The NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool report, available at http://www.reportsnreports.com/reports/276615-nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool.html, says NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019. The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim's Gilotrif, Eli Lilly's necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab) and nivolumab, Pfizer's dacomitinib and Novartis's LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.

China and India are expected to show the fastest growth over the forecast period for Asia-Pacific epilepsy therapeutics market, with CAGRs of 6.1% and 4.2%, respectively. Meanwhile, Australia and Japan will witness slightly lower CAGRs of 3.9% and 1.7%. Research states that the epilepsy sector is still dominated by older generation Anti-Epileptic Drugs (AEDs), such as carbamazepine, valproate, oxcarbazepine and phenytoin, which account for a combined share of over 60% of the APAC region's market. Historically, these AEDs have had poor safety and tolerability profiles. However, second generation AEDs with newer mechanisms of action, such as Keppra (levetiracetam), Zonegran (zonisamide) and Vimpat (lacosamide), have signaled a shift in the last decade with improved tolerability and efficacy. Recent approvals, including Fycompa (perampanel) and Trobalt (retigabine) have continued this trend by focusing on new molecular targets. Order a copy of Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability research report at http://www.reportsnreports.com/Purchase.aspx?name=276612 .

The Asia-Pacific NSCLC therapeutics industry report discusses marketed products like Alimta (pemetrexed disodium) - Eli Lilly and Company, Abraxane (nab-paclitaxel) - Celgene, Iressa (gefitinib) - AstraZeneca, Tarceva (erlotinib hydrochloride) - F. Hoffmann-La Roche, Xalkori (crizotinib) - Pfizer, Avastin (bevacizumab) - F. Hoffmann-La Roche and Gilotrif (afatinib) - Boehringer Ingelheim. Promising drug candidates in the pipeline discussed in this research include Ramucirumab (IMC-1121B) - Eli Lilly and Company, Necitumumab (IMC-11F8) - Eli Lilly and Company, Onartuzumab (MetMab) - F. Hoffmann-La Roche, Ganetespib (STA-9090) - Synta, Nintedanib (BIBF1120) - Boehringer Ingelheim, Dacomitinib (PF-00299804) - Pfizer, LDK378 - Novartis, Yervoy (ipilimumab) - Bristol-Myers Squibb and Nivolumab (BMS-936558/ONO-4538) - Bristol Myers Squibb. Order a copy of NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool research report at http://www.reportsnreports.com/Purchase.aspx?name=276615 .

Explore more reports on the pharmaceuticals market and healthcare industry at http://www.reportsnreports.com/market-research/healthcare/ .

About Us:

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:

Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

Connect With Us on:

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

SOURCE ReportsnReports.com